Ainos inc AIMD.US 總覽分析

美股醫療保健
(AIMD 無簡報檔)

AIMD 投資分析

看多重點：

  • 價值≥4
  • 股利≥2

分析結論

價值面評分較低，若以價值投資為目標，已經有長期投資部位可能需陸續減碼

AIMD 近期報酬表現

1.91%

Ainos inc

4.57%

同產業平均

3.26%

S&P500

與 AIMD 同產業的標的表現

  • APYX Apyx medical corp
    價值 2 分趨勢 3 分波段 2 分籌碼 2 分股利 1 分
    查看更多

AIMD 公司資訊

Ainos, Inc. is a diversified healthcare company, which is focused on the development of point-of-care testing (POCT), low-dose VELDONA interferon therapeutics and synthetic Ribonucleic Acid (RNA)-driven preventative medicine. Its product pipeline includes VELDONA clinical-stage human therapeutics, VELDONA Pet cytoprotein health supplements, and telehealth-friendly POCTs powered by its AI Nose technology platform. VELDONA Pet is formulated to address a variety of health issues in dogs and cats, including skin, gum, emotion, discomfort caused by allergies, eye, and weight-related issues. Its pipeline of products, which are under development, includes VELDONA human and animal drugs, VOC POCT-Ainos Flora, VOC platform-NISD co-development, VOC POCT-Ainos Pen, VOC POCT-CHS430 and Synthetic RNA. VELDONA human drugs are the high-priority programs include oral warts for human immunodeficiency virus seropositive patients, common cold, influenza and Sjogrens syndrome.

AIMD 股價